Several studies have shown that CD133+ ovarian cancer cells are more tumorigenic and more resistant to chemotherapeutic treatment than CD133− ovarian cancer cells within a heterogeneous tumor mass [8, 13-14, 37-38], even though tumor-initiating cell activity was also found in the CD133- fraction. This evidence concerns the gene PROM1 and ovarian carcinoma.